Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
534 Responses to immunotherapy based on programmed death-ligand 1 (PD-L1) copy number variation (CNV) status in patients with advanced non-small cell lung cancer (NSCLC)
Compose a Response to This Article
Other responses
No responses have been published for this article.